Published in Hepatitis Weekly, November 23rd, 1998
Pegylated 40K-interferon alpha-2a (Hoffmann-La Roche) was shown to be far more effective than regular interferon treatment in a study funded by the manufacturer presented at the 49th Annual Meeting of the American Association for the Study of Liver Diseases, held November 6-10, 1998, in Chicago, Illinois.
Data from the ongoing Phase II study, involving 155 patients, were presented by Michael Fried of the University of North Carolina at Chapel Hill.
"One of the greatest needs in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.